Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 17.50p 17.00p 18.00p 17.50p 17.50p 17.50p 2,357 06:31:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 12.82

Evgen Pharma Share Discussion Threads

Showing 476 to 493 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
16/8/2017
20:35
More research just published by the University of Maryland school of medicine; "Combination Cisplatin and Sulforaphane Treatment Reduces Proliferation, Invasion and Tumor Formation in Epidermal Squamous Cell Carcinoma" Extract From the conclusion; "Both agents suppress tumor formation, but enhanced suppression is observed with combined treatment. Moreover, both agents reduce the number of tumor-resident cancer stem cells. SFN treatment of cultured cells or tumors increases apoptosis and p21Cip1 level, and both agents increase tumor apoptosis. We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma." hTTps://www.ncbi.nlm.nih.gov/pubmed/28796401 This must be encouraging for Evgen's Metastatic Breast Cancer study.
pdt
02/8/2017
15:56
New published research on SFX-01 and Osteoarthritis "In conclusion, we report that SFX-01® improves bone microarchitecture in vivo, produces corresponding changes in bone cell behaviour in vitro to enhance indices of bone mechanical strength and produces greater symmetry in gait, without marked effects on cartilage lesion severity in STR/Ort osteoarthritic mice. Our findings support both osteotrophic roles and novel beneficial gait effects for SFX-01® that appear to be independent of articular cartilage lesion development in this model of spontaneous OA." hTTp://www.thebonejournal.com/article/S8756-3282(17)30263-6/fulltext?cc=y= I see that the work was partly funded by Arthritis Research UK And a quick search revealed that OA affects over 100m people in the US alone. The treatments all seem to be palliative and do not treat the problem.
pdt
01/8/2017
20:45
I see the RVC has put out a press release in respect of getting grant funding for a 4 year PhD study into osteoarthritis using SFX-01 hTTp://www.rvc.ac.uk/news-and-events/rvc-news/royal-veterinary-college-and-evgen-pharma-secure-funding-to-explore-treatment-for-osteoarthritis Four years seems like a long time but hopefully there will be periodic updates.
pdt
29/7/2017
17:23
timbo and paxman Thanks for posting links and comments, all very interesting and positive. I can see lots of people knocking on the Evgen door wanting to run collaborative trials over the coming months in all sorts of indications. They are a small team so hopefully it doesn't distract them from their key focus.
pdt
29/7/2017
14:03
My guess is of today Evgen have things covered pretty tight on a pharma grade compound which would meet FDA dosage rules consistently. e.g. here's a 2015 Slideshare from a member of the US's NIH addressing DMD: hTTps://www.slideshare.net/JordanGladman/gladman-nrf2-dmd Check out the last 2 pages - 'Next Steps' - collaborate with Evgen. Don't remember Evgen mentioning DMD.
paxman
29/7/2017
11:56
>>>>PDT Yes, that seems to confirm that other related compounds are likely to have similar activity which helps validate Evgen's decision to license a series of homologous compounds from The University of Seville back in November 2015 (in exchange for a small royalty ≤ 1%): https://www.investegate.co.uk/evgen-pharma-plc--evg-/rns/expands-pipeline-with-novel-compounds/201511230700055309G/ Whilst looking for the John Hopkins University ASD application (see previous post), I came across what I suspect is the patent application concerning the Saville University compounds now licensed to Evgen: https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2015110863A1&KC=A1&FT=D&ND=3&date=20150423&DB=&locale=en_EP#
timbo003
28/7/2017
16:44
Not convinced they'd have to talk to John Hopkins. Surely John Hopkins could only patent their method of storing or freezing or delivering or measuring sulforaphane, a naturally occurring molecule. SFX-01 won't need similar storage etc. Any attempt to patent human body processes would fail. Besides there's too much prior art ( research) in sulforaphane. IMHO only synthetic chemical compositions, e.g. SFX-01, are likely to be granted. I see a JH patent application in 2012 but not granted to date. Evgen are quite rightly screening loads of analogues and no doubt patenting the most promising.
paxman
28/7/2017
10:12
Thanks timbo003 - your graphs are easier to interpret than the black and white ones on page 32 of the AGM presentation.
paxman
28/7/2017
10:07
What I like is the minimal placebo effect, so any SFX-01 effect in a phase 2 should hopefully be easy to segregate. Also the reversion to pre treatment status when sulforaphane is no longer taken suggests genuine efficacy. Interesting results. I think current drugs used for autism are symptom reducers. Taking autism prevalence off the internet - about 1% of the global population - 70 million - and taking a quick look at the above data - 50% of users have a more than 20% reduction in symptoms - suggests a very large market. Hope Evgen raise some more money and accelerate all these phase 2 indications trials.
paxman
27/7/2017
16:10
Today's (unexpected) performance just has to be worth an animated gif!
timbo003
27/7/2017
11:37
Indeed PDT The slides in the appendices describing the third party studies are particularly interesting, I did not realise for example, that there are six ongoing clinical studies detailed on Clintrials.gov looking at autism. As general awareness of the Evgen stabilisation technology becomes more widespread within the academic clinical research community, along with the realization that Evegen has a unique ability to supply clinical grade, stable, Sulforaphane for clinical trials purposes, means that Steve Franklin will probably be spending more and more time dealing with the queue of academics who want to collaborate with Evgen on clinical programs.
timbo003
27/7/2017
10:47
Timbo - thanks for posting the new presentation. It is mostly the same as the presentation at the end of June however new additions are potential third party studies by Universities of Madrid and Dundee in Parkinson's and Non-alcoholic Fatty Liver disease. It is great that Evgen retains commercialization rights in these studies and just has to provide SFX. So we have had Triple Negative Breast Cancer announced a few days ago and Osteoarthritis with Royal Veterinary College announced yesterday. And Autism, Parkinson's and NAFL to follow soon.
pdt
27/7/2017
09:57
Here's the slide on the current pipeline (now added to the header) Note the investigator initiated studies (Autism and regenerative medicine), these should be a free carry for the company (except for the supply of the AS):
timbo003
27/7/2017
09:50
The AGM presentation now available on the web site: http://evgen.com/wp-content/uploads/2017/07/EVG-AGM-Presentation-Final.pdf
timbo003
26/7/2017
21:19
No sign of the AGM presentation slides yet on the Evgen web site, if they don't appear tomorrow I will chase up.
timbo003
26/7/2017
19:08
Not a big poster but a good RNS today on Manchester cancer centre doing trials on breast cancer patients. Touches everyone and gotta hope this less invasive treatment is going to work. If it does I can also treat the missus to a top holiday or two
peterm10
14/7/2017
17:22
Here is a great article summarising the research into the benefits of Sulforaphane with links to the scientific studies for each claim. A very neat summary, worth a look. hTTps://selfhacked.com/blog/panacea-benefits-broccoli-sprouts-sulforaphane/#My_Experience_With_Broccoli_Sprouts
pdt
28/6/2017
15:27
Another article about the Cancer fighting properties of Sulforaphane this time from results of work at a Korean University; hTTps://survivingmesothelioma.com/compound-in-broccoli-may-enhance-mesothelioma-treatment-with-cisplatin/
pdt
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170822 16:47:40